Efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 32, Issue 5, 2003, Pages 494-498

  Casau, Nathalie C ^a,b   Glesby, Marshall J ^a   Paul, Simon ^a   Gulick, Roy M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Combination drug therapy; HIV; Lopinavir ritonavir; Protease inhibitors; Virologic failure

Indexed keywords

ABACAVIR; AMINOTRANSFERASE; AMPRENAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE; PYRIMIDINONE DERIVATIVE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG REEXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPODYSTROPHY; LYMPHOCYTE COUNT; MALE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; NAUSEA; PRIORITY JOURNAL; SALVAGE THERAPY; SOCIAL BEHAVIOR; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS INHIBITION; VOMITING; BLOOD; DRUG COMBINATION; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; RETROSPECTIVE STUDY; VIROLOGY;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; PYRIMIDINONES; RETROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0037446299     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200304150-00005     Document Type: Article

References (15)

1. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N EngI J Med 1998;338:853-860.
2. Lucas G, Chaisson R, Moore R. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-87.
3. Mocroft A, Phillips A, Miller V, et al. The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. AIDS 2001;15:201-209.
4. Gerber J. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus. Clin Infect Dis 2000;30:S123-S129.
5. Benson C, Deeks S, Brun S, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002;185:599-607.
6. Clumeck N, Brun S, Sylte J, et al. Kaletra (ABT-378/r) and efavirenz: one-year safety/efficacy evaluation and phenotypic breakpoints in multiple PI-experienced patients [abstract 525]. 8th Conference on Retroviruses and Opportunistic Infection, Chicago, Illinois, January 31-February 4, 2001.
7. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: www.hivatis.org. Accessed April 19, 2002.
8. Gulick R, Hu J, Fiscus S, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir or both in human immunodeficiency virus-infected adults with virological failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis 2000;182:1375-1384.
9. Hammer S, Vaida F, Bennett K, et al. Dual versus single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 2002;288:169-180.
10. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N EngI J Med 1996;335:1091-1098.
11. Hellinger J, Morris A, Piscitelli D, et al. Pilot study of saquinavir-SGC (Fortovase, SQV) 1000-mg twice daily and lopinavir/ritonavir (Kaletra, LPV/r) in protease inhibitor-experienced HIV + individuals: dose escalation and combined normalized inhibitory quotient (cNIQ) [abstract 451-W]. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, February 24-28, 2002.
12. Fatkenheuer G, Romer K, Kamps R, et al. Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients. AIDS 2001;15:2334-2335.
13. Stein A, Brothers C, Scott T. Effect of reduced-dose amprenavir in combination with lopinavir on plasma levels of amprenavir in patients infected with HIV. Clin Ther 2001;23:513-515.
14. Mauss S, Schmutz G, Kuschak, et al. Unfavorable interaction of amprenavir and lopinavir in combination with ritonavir. AIDS 2002;16:296-297.
15. Fellay J, Boubaker K, Lederberger B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet. 2001;358:1322-1327.